Vaxcyte (PCVX) reported a full-year 2024 net loss late Tuesday of $3.80 per diluted share, narrower than a per-share loss of $4.14 a year earlier.
Analysts polled by FactSet expected a per-share loss of $3.91.
The company said it had cash, cash equivalents and investments of $3.13 billion as of Dec. 31, up from $1.24 billion a year earlier. Vaxcyte said the increase was mainly due to $2.2 billion in net proceeds from two follow-on financings last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.